GeoVax Labs, Inc. · NASDAQ:GOVX
GeoVax Labs — BIO CEO & Investor Conference 2025
21 slides from GeoVax Labs's conference presentation, Feb 10, 2025
Slide 1: GeoVax Corporate Overview
GeoVax Corporate Overview BIO CEO & Investor Conference February 10-11 2025 1 Nasdaq: GOVX
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstanc
Slide 3: GeoVax: Phase 2 clinical-stage biotechnology company
GeoVax: Phase 2 clinical-stage biotechnology company developing immunotherapies and vaccines against a wide range of cancers and infectious diseases Innovate Differentiate Accelerate Collaborate Unique, patented products addressing unmet medical needs Targeting populations underserved by existing pr
Slide 4: Priority Programs Advancing
Priority Programs Advancing § GEO-CM04S1: Next-generation COVID-19 vaccine – Underserved immunocompromised patients; seeking expedited authorization path – Generally healthy individuals -- BARDA Project NextGen § GEO-MVA: Mpox/Smallpox vaccine – Expand global access and supply; seeking expedited aut
Slide 5: COVID-19: GEO-CM04S1
COVID-19: GEO-CM04S1 5
Slide 6: 1st Generation vs Next-Generation COVID-19 Vaccines
COVID-19 1st Generation COVID-19 Vaccines (mRNA: Pfizer/BioNTech; Moderna; Protein subunit vaccine: Novavax) § Limited breadth of protection: Requiring reconfiguration/updating as new variants emerge (e.g., Delta, Omicron, JN.1, etc.) § Limited durability (e.g., 4-6 months vs goal of ~12 months) § I
Slide 7: BARDA Project NextGen
COVID-19 BARDA Project NextGen Phase 2b Head-to-Head Study in COVID-19 Randomized study evaluating GEO-CM04S1 vaccine with an FDA approved vaccine Collaborator N Randomization Study Population ~10,000 Pts. 1:1 Previously Vaccinated ~ 80 Sites Generally Healthy Adults Study Arms (Control vs Treatment
Slide 8: GEO-CM04S1 – Phase 2 Clinical Trials
COVID-19 GEO-CM04S1 – Phase 2 Clinical Trials (In Addition to BARDA PNG Phase 2b Trial) Immunocompromised/stem cell transplant patients § Patients with hematologic malignancies receiving stem-cell transplantation or CAR-T therapy – Highest at-risk groups for severe infection, hospitalization and dea
Slide 9: Positive Interim Data Review for Phase 2 CLL Booster Trial
COVID-19 GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, GA, November 19, 2024 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company d
Slide 10: Mpox & Smallpox: GEO-MVA
Mpox & Smallpox: GEO-MVA 10
Slide 11: WHO Declaration – Aug 14 & Nov 22
Mpox & Smallpox WHO Declaration – Aug 14 & Nov 22 11
Slide 12: Symptoms
Mpox & Smallpox Symptoms The rash tends to first develop on the face before spreading elsewhere on the body Face) 95% of cases Palms 75% lot cases, (Seep INTENSE MuscLe BACK PAIN “\30% HEADACHE ACHES of cases | sotes 75% LOWENERCY SWOLLEN SKIN RASH/ feats LYMPHNODES LESIONS.
Slide 13: What's the Solution?
Mpox & Smallpox “What’s the Solution?” WHO is coordinating global health response § WHO looking to access additional MVA-Mpox vaccine supply – Requires engaging with companies having • Experienced with the MVA-platform • MVA based Mpox vaccine candidate(s) in development • Access to existing manufac
Slide 14: GEO-MVA
Mpox & Smallpox GEO-MVA GeoVax § Currently: one supplier worldwide (MVA-BN) – unable to meet Focused on expedited demand registration for 1st U.S.- § Strong U.S. government interest in establishing a U.S. based sourced vaccine against supplier Mpox & Smallpox ‒ HHS needs to replenish/re-stock SNS (S
Slide 15: Oncology: Gedeptin®
Oncology: Gedeptin® 15
Slide 16: Gedeptin® Mechanism of Action
Oncology Gedeptin® Mechanism of Action A § Unprecedented level of B E cell-killing activity § Novel tumor killing mechanism § Facilitates destruction of D refractory solid tumors C § “Tumor agnostic” Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine ge
Slide 17: Phase 2 Plans for Gedeptin® Cancer Therapy
Oncology GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor Atlanta, GA, July 31, 2024… …The primary goal of the planned Phase 2 t
Slide 18: Milestones, Catalysts & Summary
Milestones, Catalysts & Summary 18
Slide 19: 2025 Milestones & Catalysts
2025 Milestones & Catalysts GEO-CM04S1 (Next-Generation COVID-19 Gedeptin® (Solid Tumor Therapy) – Vaccine) – Phase 2b & 2 Clinical Program Phase 2 Clinical Trial § PNG: Operational progress re trial activation § Phase 2 trial Gedeptin® + ICI: Operation progress § Immunocompromised/stem cell transpl
Slide 20: GeoVax Portfolio: Significant Revenue Opportunity
GeoVax Portfolio: Significant Revenue Opportunity Est’d Market Product Disease Target Revenue Potential $(Billion) Primary Vaccine For GEO-CM04S1 GEO-CM04S1 COVID-19 Immune Compromised $ 30.0+ Patients/Booster to mRNA GEO-MVA Gedeptin® Mpox/Smallpox Global Health Emergency $ 10+ ~$55 Billion in Mark
Slide 21: Thank You !!!
Thank You !!! 21